CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- 4 Option exercise Director acquired 19,000 shares (option exercise)
- 4 Planned sale Director sold 22,191 shares at an average $145.37 ($3,225,927)
- 4 Grant or award Chief Executive Officer acquired 17,631 shares (grant or award)
- 4 Returned to the company Director returned 13,146 shares (to the company)
- 4/A Insider Changes in Ownership
- 4 Open-market sale Senior VP, R&D sold 7,148 shares at an average $159.35 ($1,139,016)
- 4 Open-market sale Senior VP, R&D sold 4,465 shares at $165.67 ($739,717)
- 4 Option exercise Director acquired 5,000 shares (option exercise)
- 4 Open-market buy Director bought 1,615 shares at an average $124.94 ($201,776)
- 4 Open-market buy Director bought 1,200 shares at $125.45 ($150,540)
- 4 Open-market buy Chief Executive Officer bought 2,000 shares at $124.08 ($248,160)
- 4 Option exercise Director acquired 2,953 shares (option exercise)
- 4 Planned sale Chief Executive Officer sold 20,072 shares at an average $168.26 ($3,377,283)
- 4 Grant or award Director acquired 701 shares (grant or award)
- 4 Grant or award Director acquired 701 shares (grant or award)
- 4 Grant or award Director acquired 701 shares (grant or award)
- 4 Grant or award Director acquired 701 shares (grant or award)
- 4 Grant or award Director acquired 701 shares (grant or award)
- 4 Grant or award Director acquired 701 shares (grant or award)
- 4 Grant or award Director acquired 803 shares (grant or award)
Page 5 of 34 · 669 filings